Key Pomalidomide Procedures Simplified

Thus, a total of 26 case�Ccontrol studies[10-16, 29, 31-48] met inclusion criteria and were included in the current meta-analysis (Fig.?1). Characteristics and genotype distribution of each case�Ccontrol study are shown in Table?1. Figures?2-5 show the summary of meta-analysis for GSTM1and GSTT1 polymorphisms with asthma risk. When all groups were pooled, the random-effects model was conducted if the heterogeneity was significant; otherwise the fixed-effects Nutlin 3a model was conducted. Twenty-six studies with a total of 3680 cases and 4350 controls were included in the GSTM1 polymorphism meta-analysis. For the GSTT1 polymorphism, 22 studies with a total of 3167 cases and 3209 controls were included. The pooled results showed a significant association for both the GSTM1 polymorphism (null vs present, OR?=?1.452; 95% CI: 1.192�C1.770; P?selleck products 95% CI: 0.866�C7.479; P?=?0.090; I2?=?92.2%). Because Russia stretches across Europe and Asia, it was considered a distinct ethnic group in the current meta-analysis. Based on subgroup analysis by ethnicity, for GSTM1, a significant association was found for Europe (OR?=?1.303; 95% CI: 1.018�C1.667; P?=?0.036; I2?=?36.1%), Africa (OR?=?2.175; 95% CI: 1.560�C3.031; P?Oxymatrine association in Asia (OR?=?1.364; 95% CI: 0.981�C1.897; P?=?0.065; I2?=?83.2%) and Russia (OR?=?1.467; 95% CI: 0.846�C2.544; P?=?0.172; I2?=?73.4%). For GSTT1, significantly increased risk was found for Asia (OR?=?2.105; 95% CI: 1.101�C4.025; P?=?0.024; I2?=?91.9%) and Russia (OR?=?2.747; 95% CI: 1.071�C7.046; P?=?0.035; I2?=?86.4%), but not Europe (OR?=?1.381; 95% CI: 0.910�C2.096; P?=?0.130; I2?=?65.6%), Africa (OR?=?1.240; 95% CI: 0.887�C1.734; P?=?0.208; I2?=?0.0%) or Latin America (OR?=?0.920; 95% CI: 0.477�C1.775; P?=?0.804; I2?=?0.0%).